Skip to contentS
Skye Bioscience, Inc.
S
SKYESkye Bioscience, Inc. Released Nov 10, 2021, before the open
10-Q filed Nov 10, 2021, 41 days after period end · 0001516551-21-000020
Q3 2021 · 10-Q
Revenue—
Net Income-$1.82M-$1.82MN/M vs Q3 2020N/M vs Q2 2021 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
EPS Diluted$0.00$0.00N/M vs Q3 2020N/M vs Q2 2021 Operating Income-$1,819,109N/M Operating Cash Flowderived-$1,486,543N/M Free Cash Flowderived-$1,513,201N/M Filing lag
ended Sep 30, 2021 · filed Nov 10, 2021 · 41 d after period end